Outset Medical, Inc.
NASDAQ:OMMedical - Devices
+$0.73 today
- Market cap
- $57.31M
- Beta
- 1.94
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$4.07
Volume 0.05M
Average 0.16M
OM Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Outset Medical, Inc.NASDAQ: OM
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $65K (cash outflow) fell 47.2% year over year, behind the +8.7% change in trailing-twelve-month capital expenditures. Sequentially, it fell 70.9% from the prior quarter. Over 3 fiscal years it compounded at -54.2% a year.
Context
- Capital expenditures amounted to 0.7% of revenue in FY2025, down 0.1 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -47.2% toward the trailing-twelve-month pace of +8.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (798K) USD
- Year-over-year change
- +12.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (798K) | +12.5% |
| FY2024 | 2024-12-31 | (912K) | +73.5% |
| FY2023 | 2023-12-31 | (3.44M) | +58.7% |
| FY2022 | 2022-12-31 | (8.33M) | -167.9% |
| FY2021 | 2021-12-31 | (3.11M) | — |
Capital Expenditures vs competitors
How OM compares with its peers on the latest reported figures
- OM's LTM Mar 2026 capital expenditures of $740K is the 7th largest of the 10 companies compared; the peer median is $4.45M.
- Its year-over-year change of +8.7% is the 3rd highest of 8, against a peer median of -39.2%.
- Capital expenditures amounts to 0.6% of revenue for OM, versus a peer median of 10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $31.21M | -33.9% | +20.4% | 10.9% | |
| LTM Mar 2026 | $14.95M | -70.1% | +248.2% | 2419.3% | |
| LTM Mar 2026 | $9.3M | — | — | 17.3% | |
| LTM Mar 2026 | $9.13M | -39.2% | -21.2% | 2.6% | |
| LTM Dec 2025 | $4.45M | +61.0% | -16.3% | 34.2% | |
| LTM Mar 2026 | $1.44M | -65.0% | -39.4% | 1.0% | |
| LTM Mar 2026 | $740K | +8.7% | -54.2% | 0.6% | |
| LTM Mar 2026 | $246K | -70.9% | -68.9% | 109.3% | |
| LTM Mar 2026 | $73K | +113.6% | — | 0.2% | |
| LTM Mar 2026 | $0 | — | +1281.0% | 0.0% | |
| Peer median (excluding OM) | $4.45M | -39.2% | -16.3% | 10.9% | |
Competitors are the stored peer set for OM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (131.94M) | (162.96M) | (172.8M) | (127.98M) | (81.65M) |
| Depreciation & Amortization | 5.16M | 5.17M | 5.81M | 5.73M | 4.34M |
| Deferred Income Tax | 3.08M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.45M | 27.2M | 38.63M | 29.36M | 15.62M |
| Change in Working Capital | (25.6M) | (21.14M) | (773K) | (25.69M) | 2.2M |
| Accounts Receivables | (19.14M) | (2.51M) | (5.09M) | (5.01M) | 3.78M |
| Inventory | (22.04M) | (14.73M) | 1.65M | (10.86M) | 11.79M |
| Accounts Payables | (3.07M) | (1.28M) | 5.31M | (1.95M) | (3.29M) |
| Other Working Capital | 18.64M | (2.63M) | (2.64M) | (7.87M) | (10.08M) |
| Other Non-Cash Items | 1.59M | 6M | (2.25M) | 2.28M | 13.17M |
| Operating Cash Flow | (130.26M) | (145.73M) | (131.37M) | (116.3M) | (46.33M) |
| Capital Expenditures | (3.11M) | (8.33M) | (3.44M) | (912K) | (798K) |
| Acquisitions (Net) | 139.4M | 57.97M | 0 | 0 | 0 |
| Purchases of Investments | (178.43M) | (261.15M) | (172.28M) | (156.58M) | (221.97M) |
| Sales of Investments | 39.03M | 203.18M | 258.75M | 261.43M | 125.08M |
| Other Investing Activities | (139.4M) | (57.97M) | 0 | 0 | 0 |
| Investing Cash Flow | (142.51M) | (66.3M) | 83.03M | 103.94M | (97.68M) |
| Debt Repayment | 0 | 64.86M | 33.23M | 66.52M | (106.68M) |
| Common Stock Issued | 149.09M | 8.04M | 10.43M | 2.28M | 162.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.06M | 0 | 0 | (938K) | 0 |
| Financing Cash Flow | 160.15M | 72.9M | 43.65M | 67.87M | 55.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (112.62M) | (139.13M) | (4.7M) | 55.51M | (88.51M) |
| Free Cash Flow | (133.37M) | (154.05M) | (134.81M) | (117.22M) | (47.13M) |
Outset Medical, Inc.
NASDAQ:OM
Intrinsic Alpha fair value
Locked
Current Price
$3.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.